Effect of Arylamine Acetyltransferase Nat3 Gene Knockout on N-Acetylation in the Mouse

Arylamine N-acetyltransferases (NAT) catalyze the biotransformation of many important arylamine drugs and procarcinogens. NAT can either detoxify or activate procarcinogens, complicating the manner in which these enzymes may participate in enhancing or preventing toxic responses to particular agents. Mice possess three NAT isoenzymes: Nat1, Nat2, and Nat3. Whereas Nat1 and Nat2 can efficiently acetylate many arylamines, few substrates appear to be appreciably metabolized by Nat3. We generated a Nat3 knockout mouse strain and used it along with our double Nat1/2(–/–) knockout strain to further investigate the functional role of Nat3. Nat3(–/–) mice showed normal viability and reproductive capacity. Nat3 expression was very low in wild-type animals and completely undetectable in Nat3(–/–) mice. In contrast, greatly elevated expression of Nat3 transcript was observed in Nat1/2(–/–) mice. We used a transcribed marker polymorphism approach to establish that the increased expression of Nat3 in Nat1/2(–/–) mice is a positional artifact of insertion of the phosphoglycerate kinase-neomycin resistance cassette in place of the Nat1/Nat2 gene region and upstream of the intact Nat3 gene, rather than a biological compensatory mechanism. Despite the increase in Nat3 transcript, the N-acetylation of p-aminosalicylate, sulfamethazine, 2-aminofluorene, and 4-aminobiphenyl was undetectable either in vivo or in vitro in Nat1/2(–/–) animals. In parallel, no difference was observed in the in vivo clearance or in vitro metabolism of any of these substrates between wild-type and Nat3(–/–) mice. Thus, Nat3 is unlikely to play a significant role in the N-acetylation of arylamines either in wild-type mice or in mice lacking Nat1 and Nat2 activities.

[1]  D. Grant,et al.  In Vivo and in Vitro Metabolism of Arylamine Procarcinogens in Acetyltransferase-Deficient Mice , 2006, Drug Metabolism and Disposition.

[2]  M. Doll,et al.  Identification and Characterization of Functional Rat Arylamine N-Acetyltransferase 3: Comparisons with Rat Arylamine N-Acetyltransferases 1 and 2 , 2006, Journal of Pharmacology and Experimental Therapeutics.

[3]  D. Hein,et al.  N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk , 2006, Oncogene.

[4]  E. Sim,et al.  Structural analysis of the genes for human arylamine N-acetyltransferases and characterisation of alternative transcripts. , 2005, Basic & clinical pharmacology & toxicology.

[5]  F. Broackes-Carter,et al.  Arylamine N-acetyltransferase 2 Expression in the Developing Heart , 2005, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[6]  G. Fakis,et al.  Arylamine N-Acetyltransferases: What We Learn from Genes and Genomes , 2005, Drug metabolism reviews.

[7]  D. Nebert,et al.  Oral exposure to benzo[a]pyrene in the mouse: detoxication by inducible cytochrome P450 is more important than metabolic activation. , 2004, Molecular pharmacology.

[8]  P. Swiatek,et al.  Targeted Disruption of the Olfactory Mucosa-Specific Cyp2g1 Gene: Impact on Acetaminophen Toxicity in the Lateral Nasal Gland, and Tissue-Selective Effects on Cyp2a5 Expression , 2004, Journal of Pharmacology and Experimental Therapeutics.

[9]  Mario Medvedovic,et al.  4-aminobiphenyl-induced liver and urinary bladder DNA adduct formation in Cyp1a2(-/-) and Cyp1a2(+/+) mice. , 2003, Journal of the National Cancer Institute.

[10]  R. Rozmahel,et al.  Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice. , 2003, Molecular pharmacology.

[11]  A. Smith.  Intrinsic Hepatic Phenotype Associated with the Cyp1a2 Gene as Shown by cDNA Expression Microarray Analysis of the Knockout Mouse , 2003, EHP toxicogenomics : journal of the National Institute of Environmental Health Sciences.

[12]  M. Philbert,et al.  Prenatal expression of N-acetyltransferases in C57Bl/6 mice. , 2003, Chemico-biological interactions.

[13]  F. Gonzalez.  Role of Gene Knockout and Transgenic Mice in the Study of Xenobiotic Metabolism , 2003, Drug metabolism reviews.

[14]  P. Angrand,et al.  Targeted insertion results in a Rhombomere 2‐specific Hoxa2 knockdown and ectopic activation of Hoxa1 expression , 2002, Developmental dynamics : an official publication of the American Association of Anatomists.

[15]  D. Hein.  Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. , 2002, Mutation research.

[16]  E. Sim,et al.  Identification and functional characterization of novel polymorphisms associated with the genes for arylamine N-acetyltransferases in mice. , 2002, Pharmacogenetics.

[17]  D. Warshawsky,et al.  Benzo[a]pyrene-induced toxicity: paradoxical protection in Cyp1a1(-/-) knockout mice having increased hepatic BaP-DNA adduct levels. , 2001, Biochemical and biophysical research communications.

[18]  J. Crabtree,et al.  Bidirectional transcriptional activity of PGK‐neomycin and unexpected embryonic lethality in heterozygote chimeric knockout mice , 2001, Genesis.

[19]  D. Grant,et al.  Pharmacogenetics of the Human Arylamine N-Acetyltransferases , 2000, Pharmacology.

[20]  D. Nebert.  Drug-Metabolizing Enzymes, Polymorphisms and Interindividual Response to Environmental Toxicants , 2000, Clinical chemistry and laboratory medicine.

[21]  J. Ward,et al.  CYP1A2 is not the primary enzyme responsible for 4-aminobiphenyl-induced hepatocarcinogenesis in mice. , 1999, Carcinogenesis.

[22]  E. Sim,et al.  A method for genotyping murine arylamine N-acetyltransferase type 2 (NAT2): a gene expressed in preimplantation embryonic stem cells encoding an enzyme acetylating the folate catabolite p-aminobenzoylglutamate. , 1999, Biochemical pharmacology.

[23]  W. Weber,et al.  Substrate selectivity of mouse N-acetyltransferases 1, 2, and 3 expressed in COS-1 cells. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[24]  T. Rustan,et al.  Rodent models of the human acetylation polymorphism: comparisons of recombinant acetyltransferases. , 1997, Mutation research.

[25]  M. Doll,et al.  Cloning, sequencing, and recombinant expression of NAT1, NAT2, and NAT3 derived from the C3H/HeJ (rapid) and A/HeJ (slow) acetylator inbred mouse: functional characterization of the activation and deactivation of aromatic amine carcinogens. , 1997, Toxicology and applied pharmacology.

[26]  T. Ley,et al.  Long-range disruption of gene expression by a selectable marker cassette. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  T. Ley,et al.  Analysis of mice containing a targeted deletion of beta-globin locus control region 5' hypersensitive site 3 , 1996, Molecular and cellular biology.

[28]  R. Hayes,et al.  The impact of interindividual variation in NAT2 activity on benzidine urinary metabolites and urothelial DNA adducts in exposed workers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[29]  B. Wold,et al.  Know Your Neighbors: Three Phenotypes in Null Mutants of the Myogenic bHLH Gene MRF4 , 1996, Cell.

[30]  D. Grant,et al.  Structure-function studies of human arylamine N-acetyltransferases NAT1 and NAT2. Functional analysis of recombinant NAT1/NAT2 chimeras expressed in Escherichia coli. , 1994, The Journal of biological chemistry.

[31]  S. Kelly,et al.  Arylamine N-acetyltransferase in Balb/c mice: identification of a novel mouse isoenzyme by cloning and expression in vitro. , 1994, The Biochemical journal.

[32]  W. Weber,et al.  2-Aminofluorene-DNA adducts in mouse urinary bladder: effect of age, sex and acetylator phenotype. , 1992, Carcinogenesis.

[33]  W. Weber,et al.  Molecular genetic basis of rapid and slow acetylation in mice. , 1991, Molecular pharmacology.

[34]  R. Bronson,et al.  Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene , 1991, Cell.

[35]  W. Weber,et al.  2-Aminofluorene-DNA adduct formation in acetylator congenic mouse lines. , 1989, Carcinogenesis.

[36]  W. Weber,et al.  Genetic regulation of aromatic amine N-acetylation in inbred mice. , 1982, The Journal of biological chemistry.

[37]  D. Nebert.  Comparison of gene expression in cell culture to that in the intact animal: relevance to drugs and environmental toxicants. Focus on "development of a transactivator in hepatoma cells that allows expression of phase I, phase II, and chemical defense genes". , 2006, American journal of physiology. Cell physiology.

[38]  Dominic P. Williams,et al.  Development of a transactivator in hepatoma cells that allows expression of phase I, phase II, and chemical defense genes. , 2006, American journal of physiology. Cell physiology.

[39]  F. Guengerich,et al.  Cytochrome P450 activation of arylamines and heterocyclic amines. , 2005, Annual review of pharmacology and toxicology.

[40]  F. Gonzalez,et al.  Study of P450 function using gene knockout and transgenic mice. , 2003, Archives of biochemistry and biophysics.

[41]  H. Priddle,et al.  Generation and analysis of mice with a targeted disruption of the arylamine N-acetyltransferase type 2 gene , 2003, The Pharmacogenomics Journal.